Join DDW Editor Reece Armstrong and an expert line-up at the DDW Turning Science into Business Symposium at the Francis Crick Institute in London on Tuesday 4 November.

This free half-day event will feature six in-depth presentations from industry experts, a panel discussion examining new processes and technology, with a focus on how they can create efficiencies and expedite the drug discovery process, and an opportunity for networking.

The full programme has now been announced:

12.30-1.15 Registration

1.25-1.30PM Welcome from Reece Armstrong, DDW Editor

1.30-2.00PM Dr Daniil Bash, Lead Scientist at the Innovation Centre in Digital Molecular Technologies (iDMT), University of Cambridge AI-Optimisation of Flow-Based Small Molecule Organic Synthesis

2.00-2.30PM Nikhil Gupta, Principal Scientist at the Cancer Research Horizons – AstraZeneca Functional Genomics Centre Advancing Oncology Drug Discovery Through Pooled CRISPR Screening

2.30-3.00PM Lawrence Welch, Inside Sales Specialist, Nuclera Unlocking Drug Targets: 48-Hour Production of Membrane Proteins, E3 Ligases, and Transcription Factors with eProtein Discovery

3.00-3.30PM Networking coffee break Sponsored by Collaborative Drug Discovery

3.30-4.00PM Chas Bountra, Pro-Vice-Chancellor for Innovation, Professor of Translational Medicine, Oxford University Building an Ecosystem to Rival Boston or Stanford

4.00-4.30  Dr Cathy Tralau-Stewart, Executive Director of The Milner Therapeutics Institute, University of Cambridge Connecting Academic Research with Industry to Drive Therapeutic Discoveries 

4.30-5PM Professor Emma Mead, Chief Scientific Officer of the Alzheimer’s Research UK Oxford Drug Discovery Institute Innovations in Target Identification, Validation and Drug Discovery for Neurodegenerative Diseases

5.00-5.25PM Panel discussion: Technology, market forces and new ways of working – the challenges facing drug discovery and how to overcome them

Exploring the opportunity and challenges in drug discovery across neuroscience, oncology, age-related diseases and more. It will ask how technology is impacting the process for drug discovery and how the industry is responding to culture-shifts related to new ways of working.

Joanne Taylor, SVP Research, Gain Therapeutics

Nadine Clemo, VP Global Program Leader, Apollo Therapeutics

Daniel Ives, CEO and Founder, Shift Bioscience

Dr Cathy Tralau-Stewart, Executive Director of The Milner Therapeutics Institute, University of Cambridge

5.25-5.30PM Goodbye

Sponsors:

  • Nuclera (lead sponsor)
  • Collaborative Drug Discovery (coffee break sponsor)
  • Thermo Fisher Scientific (sponsor)

Registration is now open and is subject to availability and eligibility. Secure your place!